Chemical formula: C₁₉H₁₈FN₃O Molecular mass: 323.371 g/mol PubChem compound: 9931954
Rucaparib is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, including PARP-1, PARP-2, and PARP-3, which play a role in DNA repair. In vitro studies have shown that rucaparibinduced cytotoxicity involves inhibition of PARP enzymatic activity and the trapping of PARP-DNA complexes resulting in increased DNA damage, apoptosis, and cell death.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01XK03 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| RUBRACA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Rucaparib is an active ingredient of these brands:
United States (US)
Austria (AT)
Croatia (HR)
Estonia (EE)
France (FR)
Ireland (IE)
Israel (IL)
Italy (IT)
Lithuania (LT)
Netherlands (NL)
Poland (PL)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
